Allogeneic hematopoietic cell transplant appears to reduce post-transplant inpatient healthcare utilization in patients with sickle cell disease, according to a retrospective study involving 176 individuals. Participants were transplanted for sickle cell between 2000 and 2013. Investigators estimated healthcare utilization. Among the results:

• Overall, median total adjusted transplant cost per patient was nearly $470,000.
• Those with matched sibling donor and low severity had the lowest healthcare utilization compared to other donor and severity types.
• Patients with 2-year pre- and post-transplant data (n=41) showed significant admission, length of stay, and cost reductions.